Shape Biopharmaceuticals AG develops multi-target antibody-inducing immunotherapies using its fully synthetic SHAPEnano nanoparticle platform. The technology enables durable modulation of multiple pathways with ultra-low dosing and scalable peptide-like manufacturing. Our lead program targets PCSK9 and ANGPTL pathways for mixed hyperlipidemia, with in vivo proof-of-concept showing combined cholesterol and triglyceride lowering. We are advancing toward clinical candidate nomination and seek partners for R&D, EU projects, and translational development.
At Shape we develop programmable antibody inducing nanoparticle immunotherapies for cardiometabolic and other diseases. Looking for cooperations to further develop our platform and explore novel targets in cardiometabolic, I&I and immuno-oncoly areas.